

Validation data for Anti-hIL-4R-hIgG4 (S228P)

<https://www.invivogen.com/anti-human-il-4r-dupilumab-biosimilar-antibody>

For research use only

Version 25C26-AK

Anti-hIL4R-hIgG4 (S228P) is the biosimilar of the therapeutic monoclonal antibody (mAb) dupilumab. Dupilumab specifically binds to the human interleukin 4 receptor (hIL-4R). It blocks the binding of IL-4 and IL-13 and thus, inhibits the downstream STAT6-dependent pro-inflammatory response. The inhibitory activity of the biosimilar mAb Anti-hIL-4R-hIgG4 (S228P) has been validated using InvivoGen's HEK-Blue™ IL-4/IL-13 cellular assay (**Figure 1**).

Dose-dependent neutralization of IL-4 and IL-13 signaling




Figure 1. Anti-hIL-4R-hIgG4 (S228P) is a potent neutralization antibody. HEK-Blue™ IL-4/IL-13 cells were incubated with increasing concentrations of Anti-hIL-4R-hIgG4 (S228P) (0.1 ng - 10 μg) for 1 h prior to the addition of either recombinant human IL-4 (1 ng/ml) or recombinant human IL-13 (1 ng/ml). After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (mean ± SEM).

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com